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Abstract: OBJECTIVE The aim of this study was to analyze the clinical experience and outcome of
patients who have undergone pelvic exenteration for primary advanced or recurrent endometrial cancer.
METHODS We analyzed the medical records of 40 women who underwent pelvic exenteration to treat
primary advanced or recurrent endometrial cancer. RESULTS Pelvic exenteration was performed in 40
patients with primary advanced or recurrent endometrial cancer. Three patients (8%) underwent a pri-
mary exenteration, and 37 patients (92%) underwent a secondary exenteration. A total exenteration,
anterior exenteration, and posterior exenteration was performed in 85%, 5%, and 10% of patients, re-
spectively.In 31 cases, exenteration was performed with a curative aim, and in 9 cases, exenteration was
performed with a palliative aim. The overall survival rates were 61.4% at 5 years and 51.1% at 10 years.
For the 31 patients who underwent pelvic exenteration with a curative aim, the overall survival rates
were higher than those for the entire study population and were 72.6% at 5 years and 59.4% at 10 years.
For the 9 patients who underwent a palliative exenteration, the overall survival rates were 19.1% at 5
years and 0% at 10 years. This is to the best of our knowledge the biggest study of pelvic exenteration in
patients with endometrial cancer. CONCLUSIONS Our data show that pelvic exenterations are a valid
therapeutic option with long-term survival in select patients.
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The aim of this study was to analyze the clinical experience and outcome of patients who have 
undergone pelvic exenteration for primary advanced or recurrent endometrial cancer. 
Methods: 
We analyzed the medical records of 40 women who underwent pelvic exenteration to treat 
primary advanced or recurrent endometrial cancer. 
Results: 
Pelvic exenteration was performed in 40 patients with primary advanced or recurrent 
endometrial cancer. Three patients (8%) underwent a primary exenteration, and 37 patients 
(92%) underwent a secondary exenteration. A total exenteration, anterior exenteration, and 
posterior exenteration was performed in 85%, 5% and 10% of patients, respectively. 
In 31 cases, exenteration was performed with a curative aim, and in 9 cases, exenteration was 
performed with a palliative aim. The overall survival rates were 61.4% at five years and 51.1% 
at 10 years, and the disease-free survival rates were 70.5% at five years and 50.7% at 10 years. 
For the 31 patients who underwent pelvic exenteration with a curative aim, the overall survival 
rates were higher than those for the entire study population and were 72.6 % at five years and 
59.4 % at 10 years. For the nine patients that underwent a palliative exenteration, the overall 
survival rates were 19.1 % at five years and 0 % at 10 years. This is to the best of our knowledge 
the biggest study of pelvic exenteration in patients with endometrial cancer 
Conclusions:  
Our data show that pelvic exenterations are a valid therapeutic option with long-term survival 






Pelvic exenteration has been performed since December 1946 and describes a surgical 
procedure that involves the en bloc removal of reproductive organs, the bladder with the urethra, 
the pelvic ureter, the rectum and the sigmoid colon, including the anus and perineum. Alexander 
Brunschwig characterized the procedure in his article as, “the most radical surgical attack so 
far described for pelvic cancer”. The perioperative mortality rate at the time that article was 
published was 23%, and long-term survival rates were low [1]. 
Due to substantial improvements in operative and reconstructive techniques, the mortality and 
morbidity rates of pelvic exenteration have decreased and its survival rate is continuously 
increasing.  
Currently, pelvic exenteration is absolutely considered as a treatment option for select patients 
with advanced gynecologic malignancies. These patients have often suffered a recurrence after 
either operation, irradiation or both.  
The aim of this study was to analyze the outcome of patients who have undergone pelvic 
exenteration for primary advanced or recurrent endometrial cancer. These patients are normally 
older than patients with cervical cancer and, therefore, often have numerous comorbidities. Our 
data indicate that despite of these problems, pelvic exenteration for primary advanced or 
recurrent endometrial cancer is an option that is feasible with high survival rates and, therefore, 








Patients and methods 
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We retrospectively analyzed the medical records of 40 patients who underwent pelvic 
exenteration due to primary advanced or recurrent endometrial cancer. The study was approved 
by the local ethic committee.  
Exenteration was indicated as the primary treatment when the uterine tumor had infiltrated the 
bladder and/or rectum inducing fistulas. The majority of cases were secondary exenterations 
performed after an initial operation with or without irradiation treatment; in those cases, the 
indication for exenteration was tumor recurrence that met the criteria for primary exenteration.   
All patients underwent a preoperative examination under general anesthesia to verify the 
presence of a tumor histologically and to evaluate the tumor’s operability. This examination 
also included a cystoscopy and rectoscopy. Additionally, a computerized tomography (CT) scan 
was performed.  
If the CT scan showed no evidence of metastasis, no intraabdominal metastases were found 
during the operation and clear margins were pathologically confirmed, the exenteration was 
considered curative. An exenteration was considered palliative in cases with distant metastasis, 
a positive peritoneal lavage or tumor perforation into the pouch of Douglas, and when positive 
margins were detected pathologically. 
Among the 40 patients, 12 women (30%) had comorbidities, including four with hypertonia, 
two with diabetes or severe obesity, one with nicotine abuse and three with multiple 
comorbidities. 
All exenterations were performed at the Department of Gynecology of the General Hospital 
Neumarkt and the Department of Gynecologic Oncology of the University Hospital Erlangen. 
In total, seven surgeons were involved in this study. 
Anterior exenteration was defined as the removal of the uterus and vagina with the bladder, the 
pelvic ureters and the urethra, and posterior exenteration was defined as the removal of the 
reproductive tract with the recto-sigmoid colon. Total exenteration included the removal of both 
the anterior and posterior compartments. 
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Reconstruction included the formation of a continent ileocecal bladder (30/40) whenever 
possible; otherwise, conduits (4/40) and uretero-uretero-stomas (2/40) were constructed. In 
addition, 30 colonic neovaginas were generated using the caudal 10 cm of the colon above the 
resection. This portion of the colon was divided from the rest of the colon to preserve its blood 
supply and was then rotated 180°. Furthermore, the omental flap was used in 32 cases to provide 
much better pelvic filling, and this reduced the specific morbidity. Of the 40 patients, 31 (78 
%) received complete continent reconstruction.  
To restore bowel continuity, 37 colorectal or coloanal anastomoses were performed. In cases 
with high irradiation doses or extremely deep anastomosis, a temporary protective stoma was 
built for six weeks (16/40). Three patients required a permanent colostomy.  
The survival analysis was performed using Kaplan-Meier curves and Greenwood 95% 
confidence bands. Survival curves were compared using the log-rank test. Fisher’s exact test 




Three patients (8%) underwent a primary exenteration, and 37 patients (92%) underwent a 
secondary exenteration. For the secondary exenteration cases, the disease-free period from 
initial treatment to the time of exenteration ranged from 4 to 111 months, with a median of 24 
months.  
Two (5%), four (10%) and 34 (85%) patients underwent an anterior, posterior and total 
exenteration, respectively. In 31 cases (78%), exenteration was performed with a curative aim, 
and in 9 cases (23%), exenteration was performed with a palliative aim. 
The median patient age was 63.5 years with a range of 43 to 78 years. The mean follow up time 
after exenteration was 51 months, with a median of 35 months and a range of 1 to 263 months. 
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A lymphadenectomy was performed in 37 patients. Two, four, and 31 patients had undergone 
pelvic, paraaortic and both pelvic and paraaortic lymphadenectomies, respectively. Additional 
interventions, such as nephrectomy (3 cases), removal of small bowel sections (7 cases), 
removal of colon sections (3 cases) and vulvectomy (2 cases), were performed when necessary.  
Eight patients (20%) were found to have distant metastasis. Of the patients with a single 
metastasis, two had a metastasis in the abdominal wall and one each had a metastasis in the 
ovary, inguinal lymph nodes, mesentery and paravaginal tissue. Two patients showed multiple 
metastases intraoperatively. 
The tumors were grade 1 in four cases (10%), grade 2 in 14 cases (35%) and grade 3 in 20 cases 
(50%). In two cases (5%), only post-irradiation scarring was found without evidence of a tumor. 
In 29 patients (73%), the tumor entity was an adenocarcinoma.  
In 37 patients (92%), a pathological complete removal of the tumor was achieved, and three 
patients (8%) had positive margins. Two out of those 3 patients (66%), whom had undergone a 
primary exenteration, had clear margins. Clear margins were also found in 95% of patients 
(35/37) who underwent a secondary exenteration.  
In 27 cases, no lymph node metastases were found. Two patients were positive for pelvic lymph 
node metastases and one patient was positive for paraaortic lymph node metastases. 
Additionally, seven patients were positive for both pelvic and paraaortic nodal metastases. Two 
of those patients (29%) had undergone a primary exenteration (Tab. 1).  
The 30 patients with pathologically free lymph nodes had a 5-year survival rate of 63.3% and 
a 10 year survival rate of 57.0%.  
The overall survival rate was 61.4% at 5 years and 51.1% at 10 years (Fig. 1). The disease-free 
survival was 70.5% at 5 years and 50.7% at 10 years. For the 31 patients who underwent pelvic 
exenteration with a curative aim, the overall survival rates were higher than those for the entire 
study population and were 72.6% at 5 years and 59.4% at 10 years (Fig. 2).  
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For the 9 patients that underwent a palliative exenteration, the survival rate was 19.1 % at five 
years and 0% at 10 years (Fig. 2). Two of those 9  patients died, one at 2 months after 
exenteration due to sepsis and one due to general weakness. Three patients died due to distant 
pulmonary metastasis, and one patient died due to a new tumor recurrence. Three patients, who 
were all at least 60 years old, were lost to follow-up after five, eight and 108 months.  
The patients that were 43 to 55 years of age (8, 20%) had survival rates of 100% at 5 years and 
75% at 10 years. The patients that were 56 to 64 years of age (14, 35%) had a survival rate of 
61.6% at both 5 and 10 years. The patients older than 65 years (18, 45%) had survival rates of 
40.2% at 5 years and 30.2% at 10 years. The difference in the overall survival rates between 
the youngest and the oldest cohort was statistically significant (p= 0.03). (Fig. 3).The eight 
patients that were between 43 and 55 years of age had a survival rate of 100% at 5 years. They 
all underwent an exenteration with a curative aim. The tumors were graded G0 (no tumor 
residual) for 1 patient (1/8, 12.5%), G1 for 1 patient (1/8, 12.5%), G2 for 2 patients (2/8, 25%) 
and G3 for 4 patients (4/8, 50%). No patient had metastasis in the pelvic lymph nodes. One 
patient had paraaortic lymph node metastasis, and 2 patients had metastases in the mesenteric 
lymph nodes. 
Considering only the homogenous group of the 15 patients with adenocarcinoma who 
underwent exenteration with a curative aim and for whom pathological free margins were 
achieved, no lymph node metastases were present, and no evidence of lymphangiosis was 
observed, we achieved a survival rate of 77.5% at 5 years and of 64.6% at 10 years. 
 
Complications occurred in 12 of the 40 patients (30%). Seven patients had one complication, 
such as abscess formation, ileus, fistula, lymph cyst, septicemia, thrombosis, etc. Two patients 
had two complications, and 3 patients had more than two complications. 
In this study, which included many elderly patients, the cause of death was local recurrence for 
2 patients and distant metastasis for 5 patients. For 12 patients, the cause of death was not tumor 
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related. At the time of this publication, 2 patients were still living, and their lung metastases 
had been removed. The perioperative mortality rate (30 postoperative days) was 7.5% (3/40).  
 
Discussion 
The main indication for pelvic exenteration is the central persistence or recurrence of 
gynecologic cancers. A major issue when comparing published data regarding pelvic 
exenterations is the heterogeneity of patient groups. In numerous papers, patients with different 
gynecologic cancers are not analyzed separately; therefore, the results of those papers should 
be interpreted with caution. The study presented here describes a series of a single gynecologic 
cancer entity, endometrial cancer, and solely depicts clinical outcome after pelvic exenteration. 
Although many parameters, such as perioperative morbidity and mortality rates after pelvic 
exenteration, are similar between different cancer types, there are some interesting distinctions 
that require closer consideration. 
The first reported perioperative mortality rate for pelvic exenteration for primary advanced or 
recurrent endometrial carcinoma was 23% [1,2], and this has decreased to between 0 and 10% 
[3, 4, 5, 6]. In our study, there were no intraoperative deaths, and the perioperative mortality 
rate was 7.5%. 
Morbidity rates of up to 75% have been reported by earlier publications [3,6,7,8,9]. Due to 
improvement in perioperative care, operative morbidity has noticeably declined over the last 
few decades. Our complication rate of 30% is within the reported range for pelvic exenteration, 
although 37 of our 40 patients (92%) were pretreated, and the majority of them were pretreated 
more than once (24/37, 65%). Regardless of these pretreatments, we achieved complete 
continent reconstruction of the neo-bladder and colon in 80% (32/40) of our patients. Of the 
initial 18 patients who underwent a protective colostomy, 8 were resected and 10 were 
maintained due to patient request.  
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The 5-year overall survival rate of the 40 patients with primary advanced or recurrent 
endometrial cancer was 61.4 %. The best outcome was observed in the youngest age group (43-
55 years). All women in that group survived 5 years. For this age group, no advantage was 
found in regards to negative prognostic features, such as high grading (G3: 4/8, 50%). The 
oldest patient group (>65 years) had a 5-year survival rate of 40.2% and a 10-year survival rate 
of 30.2%, which indicates that pelvic exenteration is still a viable option for these patients, with 
a long-term survival rate. Furthermore, these data are in accordance with those of other authors 
[8, 9 10, 11, 12-17]. 
For patients undergoing pelvic exenteration with a curative intent, the survival rate of patients 
with primary advanced or recurrent cervical cancer is higher than that of patients with 
endometrial cancer: 72.6 % vs. 64% at 5 years and 59.4% vs. 57% at 10 years [25]. However, 
due to the small cohort in this study, this difference was not statistically significant (p= 0.70).  
This difference in survival rate may be due to the different biological behaviors (parametrial vs 
nodal invasion) of these two cancer entities and once again indicates the problem of analyzing 
outcomes after pelvic exenterations in an inhomogeneous cohort. Another observed difference 
between endometrial and cervical cancer is the presence of mesorectal lymph node metastasis 
without infiltration of the rectum. While mesocolic lymph node metastasis clearly decreases the 
5-year overall survival of patients with cervical cancer [25], this was not found in patients with 
endometrial cancer . Of three patients with mesocolic lymph node metastasis, 2 patients 
experienced long-term survival with no other lymph node metastases, and one patient died after 
R1 resection shortly after the operation.  
When major symptoms, such as pelvic pain, bowel obstruction and fistula formation, 
substantially reduce patient quality of live, palliative exenteration may be considered, not only 
to improve quality of live but also to improve survival. In support of this, the patients in our 
study who underwent palliative exenteration had a 5-year survival rate of 19.1%. Other therapy 
options, such as chemotherapy, radiation and the combination of the two, show overall survival 
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rates of a few months and sometimes cause severe side effects. In a phase II trial, patients with 
persistent or recurrent endometrial cancer receiving bevacizumab had a median progression 
free survival of 4.2 months and an overall survival of 10.5 months [26]. Several other phase II 
and III trials with single agent chemotherapy showed a limited response rate that typically lasted 
for only several months [27]. Due to the lack of alternative effective treatment options, pelvic 
exenteration may be a reasonable alternative. 
Although patients with primary advanced endometrial cancer represent only a small portion of 
patients with newly diagnosed uterine cancers, they have a high percentage of disease-related 
deaths, with low survival rates in patients with advanced stage or recurrent disease [18, 19, 20, 
21, 23, 26, 27]. Women with advanced stage or recurrent disease are often multimorbid, obese 
and older than women with other uterine cancers; thus, frequently, they are not considered ideal 
candidates for extensive surgeries, such as pelvic exenteration, even though studies have shown 
that mortality can be decreased when surgery is performed [22].  
The limitations of our study are its retrospective character and relatively small cohort. However, 
the 40 cases presented here represent the largest patient cohort with advanced or locally 
recurrent endometrial cancer who underwent pelvic exenteration published to date. Only a few 
studies have compared pelvic exenteration to radiotherapy, and we did not find any studies that 
compared exenteration to chemotherapy. The limited data available demonstrate that pelvic 
exenteration may provide some benefit over radiation, although larger studies are necessary to 
support this finding [24].  
Improvements in operative technique have resulted in the more frequent achievement of 
pathological free margins. There are limited treatment options available for women with 
advanced or recurrent endometrial cancer, and exenteration is the only treatment that provides 
the possibility of cure. Our finding of a five-year overall survival rate of 61.4 % supports the 
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Fig. 1: Overall survival after pelvic exenteration in patients with primary advanced or 
recurrent endometrial cancer (Kaplan–Meier curve). 
 
Fig. 2: Overall survival after pelvic exenteration in patients according to curative or 
palliative aim (Kaplan–Meier curves). 
 
Fig. 3: Overall survival after pelvic exenteration according to age group (Kaplan–Meier 
curves). 
 
Tabl.: 1 Lymph node status at initial treatment and exenteration 
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